The GLP-1 Pill Is Almost Here. What You Need to Know About Orforglipron
- t2diabetesnetwork
- 3 days ago
- 4 min read
Written by Clare Koning, RN, PhD
T2D Network | April 2026 | 6 min read
Key Highlights
✅ Orforglipron is a once-daily GLP-1 pill: no injections, no food or water timing restrictions
✅ Phase 3 trials showed A1C reductions of 1.3%–1.6% and meaningful weight loss
✅ In a head-to-head trial published in The Lancet, it outperformed oral semaglutide on every key endpoint
✅ Regulatory submissions are underway in 40+ countries: U.S. diabetes approval anticipated later in 2026
✅ Not yet approved in Canada: but worth knowing about now
If you've ever wished the GLP-1 medications that have transformed diabetes care could come in a simple daily pill, without needles, refrigeration, or strict timing around meals, you may be closer to that reality than you think.
Orforglipron, an investigational once-daily oral GLP-1 receptor agonist developed by Eli Lilly, has just completed a series of landmark Phase 3 trials. The results are turning heads in the diabetes community, and for good reason.
Here's what the evidence actually says, and what it might mean for people living with type 2 diabetes.
What Is Orforglipron?
GLP-1 receptor agonists (like semaglutide, sold as Ozempic or Rybelsus) work by mimicking a gut hormone that helps regulate blood sugar, suppress appetite, and promote weight loss. Until now, the most effective versions have been injectables.
Orforglipron is different. It's a small molecule, meaning it's not a peptide and doesn't break down in the gut the way most protein-based GLP-1 drugs do. That allows it to be taken as a pill, once a day, at any time, without restrictions on food or water intake. That last point matters more than it sounds: existing oral semaglutide (Rybelsus) must be taken 30 minutes before eating, with only a small amount of water, a barrier that can be frustrating in real life.
What Do the Trials Show?
The data are genuinely impressive.
In ACHIEVE-1, the first of seven Phase 3 studies in people with type 2 diabetes, orforglipron reduced A1C by an average of 1.3% to 1.6% across doses compared to placebo at 40 weeks, starting from a baseline of 8.0%. Over 65% of participants on the highest dose achieved an A1C at or below 6.5%, the target many healthcare providers aim for. The pill also produced an average weight loss of about 7.9% (roughly 16 lbs) at the highest dose.
Then came ACHIEVE-3, published in The Lancet in February 2026, the first direct head-to-head comparison between two oral GLP-1 therapies. In this 52-week trial of 1,698 people with type 2 diabetes whose blood sugar wasn't adequately controlled on Metformin, orforglipron outperformed oral semaglutide on every primary and secondary endpoint, including A1C reduction and weight loss, with improvements visible as early as four weeks.
In ATTAIN-2, which specifically studied people with both obesity and type 2 diabetes (a group for whom weight loss is known to be harder), participants on the highest dose lost an average of 10.5% of body weight (about 23 lbs) over 72 weeks, while also reducing A1C by an average of 1.8%.
Across all studies, the safety profile was consistent with the broader GLP-1 class: nausea, diarrhea, and mild gastrointestinal symptoms were the most common side effects, typically occurring during the dose escalation phase.
Why Does This Matter for People with T2D?
For many people, the barrier to starting a GLP-1 therapy isn't about the medicine itself, it's about the needle. Injection anxiety, needle phobia, and the practicalities of cold storage and travel all limit uptake of otherwise effective treatments.
An oral alternative that works as well as or better than existing options, and can be taken as easily as a daily vitamin, has the potential to meaningfully expand access.
Researchers at UTHealth Houston described orforglipron's potential to become "the Metformin of obesity", a widely accessible, affordable, and scalable first-line treatment. Whether that vision is fully realized will depend on pricing, insurance coverage, and regulatory outcomes.
Where Things Stand Right Now
Lilly has submitted orforglipron for regulatory review in over 40 countries. In the U.S., a submission for the weight management indication was made in 2025, with a type 2 diabetes submission planned later this year. Canadian regulatory timelines typically follow U.S. approvals, so Canadians living with type 2 diabetes may be waiting a little longer.
It is not yet approved anywhere for type 2 diabetes. But given the strength of the trial data, it's a development worth watching closely.
In the meantime, if you're interested in GLP-1 therapies or want to discuss your current diabetes medications, this is a great conversation to have with your healthcare provider. There are already approved options, injectable and oral, that may be right for you now.
What Should You Do?
Talk to your diabetes care team about whether a GLP-1 receptor agonist is appropriate for you — approved options already exist.
Stay informed. The T2D Network will continue to share updates as orforglipron moves through the regulatory process in Canada.
Don't discontinue or switch medications without medical guidance. Orforglipron is not yet approved, and self-managing medication changes is never recommended.
This blog is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management.
